AS1411-Induced Growth Inhibition of Glioma Cells by Up-Regulation of p53 and Down-Regulation of Bcl-2 and Akt1 via Nucleolin. [PDF]
AS1411 binds nucleolin (NCL) and is the first oligodeoxynucleotide aptamer to reach phase I and II clinical trials for the treatment of several cancers.
Ye Cheng +8 more
doaj +2 more sources
AS1411 is a nucleolin-binding aptamer which attracted great interest as active targeting ligand for the selective delivery of therapeutic agents to tumour cells. In this work we selected three AS1411 derivatives 5'-conjugated with lipophilic tails and studied their properties in view of their application in liposomial formulations and/or lipid coated ...
Riccardi Claudia +6 more
core +6 more sources
Exploring the G-Quadruplex Formation of AS1411 Derivatives
AS1411 is a G-quadruplex (G4) aptamer that binds tightly to nucleolin (NCL) on the cell surface and has shown strong anticancer effects. However, this aptamer is highly polymorphic, presenting different types of G4s, which may hinder its preclinical ...
Pedro Lourenço +9 more
doaj +2 more sources
Bioactivity of 2'-deoxyinosine-incorporated aptamer AS1411. [PDF]
AbstractAptamers can be chemically modified to enhance nuclease resistance and increase target affinity. In this study, we performed chemical modification of 2′-deoxyinosine in AS1411, an anti-proliferative G-rich oligodeoxynucleotide aptamer, which binds selectively to the nucleolin protein.
Fan X, Sun L, Wu Y, Zhang L, Yang Z.
europepmc +4 more sources
Enhancement of Radiosensitization by Silver Nanoparticles Functionalized With Polyethylene Glycol and Aptamer As1411 for Glioma Irradiation Therapy [PDF]
Dongdong Li, Jing Zhao, Peidang Liu
exaly +2 more sources
Degradation of dual proteins induced by “power train” [PDF]
Targeted degradation of multiple oncogenic membrane proteins remains challenging due to inefficient lysosomal trafficking and off-target effects, which limits the application of current monovalent aptamer systems.
Rui Liang +9 more
doaj +2 more sources
Synthesis and Evaluation of AS1411-Lenalidomide-Targeted Degradation Chimera in Antitumor Therapy [PDF]
Background: High expression of nucleolin (NCL) on the surface of tumor cells is closely associated with disease progression and poor prognosis. The aptamer–PROTAC conjugate (APC) technology provides a novel molecular design strategy for the targeted ...
Xueling Ma +11 more
doaj +2 more sources
Advances in Aptamer Drug Delivery Systems for Treatment of Glioblastoma. [PDF]
Aptamers have remarkable recognition capacity which is suitable for assisting drug delivery for GB. This review demonstrates that aptamers have great potential as targeted therapeutic carriers, conjugated to various therapeutic carriers, using a range of conjugation strategies and chemistries.
Paul AR +4 more
europepmc +2 more sources
Colorectal cancer (CRC) poses a global health challenge, with current treatments often harming both cancerous and normal cells. To improve efficacy, a multifunctional drug delivery platform has been developed, integrating bioactive materials, anticancer ...
Kanpitcha Jiramitmongkon +4 more
doaj +2 more sources
Multi-Technique Integration Identifies O-GlcNAc Transferase in Fibroblast-Like Synoviocytes as a Therapeutic Target for Rheumatoid Arthritis. [PDF]
AI‑guided single‑cell transcriptomics identifies OGT as a key regulator enriched in rheumatoid arthritis fibroblast‑like synoviocytes (RA‐FLSs). Inflammatory stimuli activate the OGT–SAP130 axis, which modulates the H3K27ac/H3K27me3 balance and epigenetically silences BTG2, promoting aggressive transformation of RA‑FLSs.
Xie D +14 more
europepmc +2 more sources

